- Lobbying
- Lobbying by BioMarin Pharmaceutical, Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jack Baer | Legislative Assistant for Congressman Chip Cravaack (R-MN) Legislative Assistant-Congressman Chip Cravaack |
Lindsay Punzenberger | Legislative Assistant for Congressman Thomas E. Petri (R-WI) |
Noelle Lundberg | Legislative Director for Chairman Bill Archer (R-TX) Legislative Director - Chairman Bill Archer |
Tim Carey | Legislative Director for Representative Brad Sherman (D-CA) Legislative Director for U.S. Representative Brad Sherman (D-CA), Deputy Legislative Director for Representative Anna G. Eshoo (D-CA Legislative Director-Rep Brad Sherman Legislative Director - Rep Brad Sherman |
Elizabeth Lee | Senior Policy Advisor to the Administrator of the Health Resources and Services Administration, legislative aide to Senator Tammy Baldwin |
Michael Spira | Chief of Staff for former Congresswoman Carolyn McCarthy (D-NY) and Deputy Chief of Staff for Congressman Ed Perlmutter (D-CO) |
Jessica Layson Davis | Legislative Director for Rep. Austin Scott (R-GA) |
Brian Beaty | staff for Sen. Mark Warner (D-VA) staff of Sen. Mark Warner (D-VA) |
Thomas Garrigan | Associate Legislative Asst for Sen.Sheldon Whitehouse (D-RI) |
Jessica Layson | Legislative Director for Rep. Austin Scott (R-GA) |
Stephanie Silverman | n/a |
Amy Redl | n/a |
Elizabeth Brooks | n/a |
Lauren Reliford | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate,
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate,
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Registration
Issue(s) they said they’d lobby about: Orphan drugs and rare diseases, matters related to reimbursement policy.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate